My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Result Updates | Nov 17th 2016

Sun Pharmaceuticals Industries Ltd

CMP : 683Target Price : 847

Sun Pharma posted numbers better than expected on OPM and net profit front. Sales came in at Rs7,764cr vs. Rs7,800cr expected vs. Rs6,858cr in 2QFY2016, posting a yoy growth of 13.2%. On the operating front, the EBITDA margin came in at 34.3% vs. 30.1% expected and vs. 27.1% in 2QFY2016. Lower expenses during the quarter aided the OPM exp..

View As PDF

Result Updates | Nov 16th 2016

Ipca Laboratories Ltd

CMP : 540Target Price : 613

Ipca Laboratories posted numbers lower than expected on the net profit and OPM front. On sales front, the company posted sales of Rs853cr (vs. Rs750cr expected vs. Rs739cr in 2QFY2016), posting a yoy growth of 15.5%. On the operating front, the EBITDA margin came in at 12.8% vs. 14.9% expected vs. 10.6% in 2QFY2016. Consequently, the Adj...

View As PDF

Sort By

Result Updates | Nov 16th 2016

Aurobindo Pharma Ltd

CMP : 733
Target Price : 877

Aurobindo Pharma (APL) posted numbers lower than expected on sales and net profit front, while OPM was more or less in line with expectations. On sales front, the company posted sales of Rs3715cr vs. Rs3,900cr expected vs. Rs3,280cr in 2QFY2016, posting a yoy growth of 13.3%. On the operating front, the EBITDA margin came in at 23.4% vs. ..

Result Updates | Nov 16th 2016

Mirza International Ltd

CMP : 80
Target Price : 107

We expect MIL to report a net revenue CAGR of ~9% to ~Rs1,106cr over FY2016-18E on back of strong growth in domestic branded sales (owing to aggressive ad spend and addition in the number of EBOs & multi-brand outlets [MBOs]) and healthy export revenues. On the bottom-line front, we expect a CAGR of ~9% to Rs92cr over the same period ..

Result Updates | Nov 16th 2016

Garware-Wall Ropes Ltd

CMP : 550
Target Price : 618

Going ahead, we expect GWRL to report a healthy topline in anticipation of strong domestic as well as export sales. On the domestic front, we expect demand to pick up with an expected growth in the agriculture and fisheries segments in the country. Further, we expect the company to continue reporting strong numbers on back of higher deman..

Result Updates | Nov 11th 2016

ICICI Bank Ltd

CMP : 277
Target Price : 315

ICICI Banks 2QFY17 results have been encouraging. While slippages remained high, large part of that came from the watch list. The bank has utilized part of the proceeds from stake sale in insurance business towards provisions. Management commentary also remained optimistic, as no addition is expected to the watch list; sharp deterioration..

Result Updates | Nov 11th 2016

Cipla Ltd

CMP : 564
Target Price : 490

Cipla posted numbers lower than expected for 2QFY2017. The company posted sales of Rs3,672cr vs. Rs3,737cr expected, registering a yoy growth of 8.7%, mainly aided by domestic formulations. Domestic formulation (Rs1,522cr) grew by 11.3% yoy, while exports (Rs2150cr) grew by 7.5% yoy. On the operating front, the EBITDA margin came in at 16..

Result Updates | Nov 11th 2016

Lupin Ltd

CMP : 1,493
Target Price : 1,809

Lupin posted results lower than expected. Sales came in at Rs4,212cr vs. Rs4,300cr expected, registering a yoy growth of 31.9%, mainly aided by exports. The sales growth was driven by Formulations sales (Rs3,919.3cr), posting a yoy growth of 37.1%; while API sales (Rs291.9cr) posted a yoy de-growth of 12.3%. On the operating front, the EB..

Result Updates | Nov 10th 2016

Indoco Remedies Ltd

CMP : 277
Target Price : 240

Indoco Remedies posted sales of Rs276cr vs. Rs248cr in 2QFY16, up by 11.6% yoy, mainly on back of domestic sales (Rs168.8cr, which grew by 22.0% yoy). Overall, the formulations, which posted sales of RS261.4cr grew, by 13.0% yoy. The API (Rs135.9cr) dipped by 11.0% yoy. On the operating front, the gross margin came in at 64.9% (65.0% expe..

Result Updates | Nov 10th 2016

Sanofi India Ltd

CMP : 4,277
Target Price :

Sanofi India posted results and are below expectations on all fronts. The sales came in at Rs583cr vs. Rs600cr expected, posting a yoy growth of 5.4%. According to AIOCD, secondary sales, growth for Sanofi India was double digit. According to AIOCD, regulatory actions will have negative one-time impact of ~2% on sales of the company. We e..

Result Updates | Nov 09th 2016

Glaxosmithkline Pharma Ltd

CMP : 2,719
Target Price :

For 2QFY2017, sales stood at Rs783cr vs. Rs700cr expected and vs. Rs700cr in 2QFY2016, a yoy growth of 11.8%. On the operating front, the OPM came in at 15.9% vs. 17.2% in 2QFY2016 and vs. 17.0% expected. The company’s OPM was impacted by other expenses, which grew by 40.5% yoy. Thus, the company posted an Adj. net profit of Rs98cr vs. Rs..

Result Updates | Nov 08th 2016

Amara Raja Batteries Ltd

CMP : 1,010
Target Price : 1,167

We believe that ARBL is likely to continue gaining market share in the automotive battery segment. The strategy followed by automotive OEMs of sourcing from multiple vendors as against having a single vendor is likely to benefit ARBL. Further, with the company’s strengthening distribution network in the Western and Eastern markets, we exp..